Turning Point Therapeutics, Inc. Revenue
Turning Point Therapeutics, Inc. reported Revenue of $119.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2022-08-08
- Turning Point Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-06-30 was $119.00K, a 97.70% decline year-over-year.
- Turning Point Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-03-31 was $429.00K, a 98.30% decline year-over-year.
- Turning Point Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-12-31 was $0.00.
- Turning Point Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-09-30 was $460.00K, a 98.16% decline year-over-year.
- Turning Point Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $30.83M, a 23.32% increase from fiscal 2020.
- Turning Point Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $25.00M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-06-30 | $119.00K 10-Q · filed 2022-08-08 | $548.00K 10-Q · filed 2022-08-08 | $548.00K derived: sum of 3 quarters · filed 2022-08-08 | $1.01M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $429.00K 10-Q · filed 2022-05-10 | $429.00K derived: sum of 2 quarters · filed 2022-05-10 | $889.00K derived: sum of 3 quarters · filed 2022-05-10 | $6.05M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $460.00K derived: sum of 2 quarters · filed 2022-02-28 | $5.62M derived: sum of 3 quarters · filed 2022-08-08 | $30.83M 10-K · filed 2022-02-28 |
| 2021-09-30 | $460.00K 10-Q · filed 2021-11-09 | $5.62M derived: sum of 2 quarters · filed 2022-08-08 | $30.83M 10-Q · filed 2021-11-09 | $30.83M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-06-30 | $5.16M 10-Q · filed 2022-08-08 | $30.37M 10-Q · filed 2022-08-08 | $30.37M derived: sum of 3 quarters · filed 2022-08-08 | $55.37M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $25.20M 10-Q · filed 2022-05-10 | $25.20M derived: sum of 2 quarters · filed 2022-05-10 | $50.20M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $25.00M derived: sum of 2 quarters · filed 2022-02-28 | $25.00M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $25.00M 10-Q · filed 2021-11-09 | $25.00M 10-Q · filed 2021-11-09 |